Trial Profile

Relevance of Maintenance Therapy Using Lenalidomide (Revimid) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 29 Apr 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary)
Indications Multiple myeloma
Focus Registrational; Therapeutic Use

Most Recent Events

25 Apr 2019 Status changed from active, no longer recruiting to completed.
03 Jan 2018 Planned End Date changed from 1 Sep 2017 to 1 Sep 2020.
24 Feb 2017 According to a Celgene Corporation media release,the European Commission approved REVLIMID as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma after Autologous Stem Cell Transplantation.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com